Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corcept Therapeutics ( (CORT) ) has provided an update.
On February 24, 2026, Corcept Therapeutics reported audited fourth-quarter and full-year 2025 results, with revenue rising to $202.1 million in the quarter and $761.4 million for the year, driven by stronger demand in its Cushing’s syndrome business despite supply and pharmacy transition constraints. Full-year 2025 net income declined to $99.7 million from $141.2 million in 2024, cash and investments fell to $532.4 million as the company spent $245.9 million on share repurchases, and management issued 2026 revenue guidance of $900 million to $1 billion, signaling confidence in long-term growth.
The company highlighted significant clinical and regulatory momentum, including ongoing engagement with the FDA following a Complete Response Letter for relacorilant in Cushing’s syndrome and active review of its NDA for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, supported by Phase 3 ROSELLA data showing a 35 percent reduction in risk of death. Across oncology, MASH and ALS, Corcept is advancing multiple mid- and late-stage trials — including the MONARCH Phase 2b MASH study, BELLA and other solid tumor programs, and a planned Phase 3 dazucorilant ALS trial — positioning the company for potential new indications that could broaden its revenue base and reinforce its standing in cortisol-modulating therapies.
The most recent analyst rating on (CORT) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Neutral.
The score is primarily supported by strong financial health (very low leverage, solid ROE, high gross margin) and constructive business momentum from guidance and pipeline progress. These positives are meaningfully offset by very weak technical trend signals (price far below major moving averages) and profitability/cash-flow pressure, with valuation (high P/E) and mixed regulatory outcomes adding risk.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on discovering and developing medications that treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The company markets therapies for Cushing’s syndrome and is advancing a broad pipeline, including relacorilant, miricorilant and dazucorilant, targeting conditions such as ovarian and other solid tumors, metabolic dysfunction-associated steatohepatitis and amyotrophic lateral sclerosis.
Average Trading Volume: 2,087,825
Technical Sentiment Signal: Sell
Current Market Cap: $4.19B
For a thorough assessment of CORT stock, go to TipRanks’ Stock Analysis page.